Kidney Function Decline and Serious Adverse Drug Reactions in Patients With CKD
2023
Laville, Solène | Gras-Champel, Valérie | Hamroun, Aghilès | Moragny, Julien | Lambert, Oriane | Metzger, Marie | Jacquelinet, Christian | Combe, Christian | Fouque, Denis | Laville, Maurice | Frimat, Luc | Robinson, Bruce | Bieber, Brian | Stengel, Bénédicte | de Pinho, Natalia Alencar | Massy, Ziad | Liabeuf, Sophie | Ayav, Carole | Briançon, Serge | Cannet, Dorothée | Combe, Christian | Fouque, Denis | Frimat, Luc | Herpe, Yves-Edouard | Jacquelinet, Christian | Pascal, Christophe | Robinson, Bruce | Lange, Céline | Legrand, Karine | Metzger, Marie | Speyer, Elodie | CHU Amiens-Picardie | Mécanismes physiopathologiques et conséquences des calcifications cardiovasculaires - UR UPJV 7517 (MP3CV) ; Université de Picardie Jules Verne (UPJV)-CHU Amiens-Picardie | Université de Lille | Centre Hospitalier Régional Universitaire [CHU Lille] (CHRU Lille) | Centre de recherche en épidémiologie et santé des populations (CESP) ; Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Saclay | Université de Versailles Saint-Quentin-en-Yvelines (UVSQ) | Agence de la biomédecine [Saint-Denis la Plaine] | Bioingénierie tissulaire (BIOTIS) ; Université de Bordeaux (UB)-Institut National de la Santé et de la Recherche Médicale (INSERM) | Centre Hospitalier Universitaire de Bordeaux (CHU Bordeaux) | Cardiovasculaire, métabolisme, diabétologie et nutrition (CarMeN) ; Université Claude Bernard Lyon 1 (UCBL) ; Université de Lyon-Université de Lyon-Hospices Civils de Lyon (HCL)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE) | Centre Hospitalier Lyon Sud [CHU - HCL] (CHLS) ; Hospices Civils de Lyon (HCL) | Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy) | Adaptation, mesure et évaluation en santé. Approches interdisciplinaires (APEMAC) ; Université de Lorraine (UL) | University of Michigan [Ann Arbor] ; University of Michigan System | Arbor Research Collaborative for Health | Hôpital Ambroise Paré [AP-HP] | Chronic Kidney Disease - Réseau Epidémiologie et Information en Néphrologie (CKD REIN) ; Institut National de la Santé et de la Recherche Médicale (INSERM) | Centre d'investigation clinique [Nancy] (CIC) ; Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lorraine (UL)
International audience
Show more [+] Less [-]English. Rationale & ObjectiveAdverse drug reactions (ADRs) are common in patients with chronic kidney disease (CKD). The impact of kidney function decline on serious ADR risk has been poorly investigated. We sought to comprehensively describe ADRs and assess the relationship between eGFR and serious ADR risk.Study DesignProspective cohort study.Setting & Participants3,033 participants in French Chronic Kidney Disease-Renal Epidemiology and Information Network (CKD-REIN) cohort study, a nationwide sample of nephrology outpatients with moderate-to-advanced CKD.PredictorsDemographic and biological data (including eGFR), medication prescriptions.OutcomesADRs (preventable or not) were prospectively identified from hospital discharge reports, medical records, and patient interviews. Expert pharmacologists used validated tools to adjudicate ADRs.Analytical ApproachRestricted cubic splines in fully adjusted cause-specific Cox proportional hazard models were used to evaluate the relationship between eGFR and the risk of serious ADRs (overall and by subtype).ResultsDuring a median follow-up period of 4.7 years, 360 patients experienced 488 serious ADRs. Kidney and urinary disorders (n=170) and hemorrhages (n=170) accounted for 70% of serious ADRs. The most common medications classes were antithrombotics and renin-angiotensin system inhibitors. The majority of those serious ADRs were associated with hospitalization (n=467), with 32 directly or indirectly associated with death, and 22 associated with life-threatening event. More than 27% of the 488 serious ADRs were preventable or potentially preventable. The eGFR is a major risk factor for serious ADRs. Risk of AKI was 2.2% higher and risk of bleeding ADRs were 8% higher for each 1 mL/min/1.73m2 lower baseline eGFR.LimitationsThe results cannot be extrapolated to patients who are not being followed up by a nephrologist.ConclusionsADRs constitute a major cause of hospitalization in CKD patients for whom lower eGFR level is a major risk factor.
Show more [+] Less [-]Bibliographic information
This bibliographic record has been provided by Institut national de la recherche agronomique